Valuation: PREDILIFE

Market Cap 3.35M 3.76M 3.12M 2.84M 5.34M 356M 5.43M 37.45M 14.65M 186M 14.1M 13.8M 594M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 8.13M 9.11M 7.56M 6.87M 12.93M 863M 13.17M 90.79M 35.52M 450M 34.19M 33.46M 1.44B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day-5.56%
1 week-6.59%
Current month-15.84%
1 month-16.67%
3 months-52.91%
6 months-72.49%
Current year-71.76%
1 week 0.85
Extreme 0.85
0.9
1 month 0.85
Extreme 0.85
1.02
Current year 0.85
Extreme 0.85
4
1 year 0.85
Extreme 0.85
4
3 years 0.85
Extreme 0.85
24
5 years 0.85
Extreme 0.85
24
10 years 0.85
Extreme 0.85
24
Manager TitleAgeSince
Chief Executive Officer 56 2003-12-31
Chief Tech/Sci/R&D Officer - 2006-12-31
General Counsel - 2015-12-31
Director TitleAgeSince
Chairman 56 2003-12-31
Director/Board Member 46 2017-12-31
Director/Board Member 58 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/27/23 Buy

Chief Executive Officer

1,200 0.0328%
3/23/22 Sell

Chief Executive Officer

3,000 0.0820%
3/9/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
-5.56%-6.59%-73.44%-85.22% 3.95M
+0.21%-4.63%+55.34%+71.32% 68.92B
+1.66%+7.51%+8.12%+60.04% 51.9B
+3.14%+7.17%+12.48%+44.42% 48.73B
+3.45%+4.70%+33.44%+35.96% 43.13B
-2.20%+0.61%+281.88%+532.76% 41.48B
+6.43%+6.84%+18.32%+109.23% 39.96B
+1.28%+1.39%+11.69%+45.10% 30.6B
+2.18%-7.86%+35.35%+1.27% 26.01B
+1.74%-2.02%-13.55%-12.92% 22.27B
Average +1.22%-1.51%+36.96%+80.20% 37.3B
Weighted average by Cap. +1.87%-0.25%+52.77%+105.45%

Financials

2024 2025
Net sales 493K 553K 458K 417K 784K 52.33M 799K 5.51M 2.15M 27.31M 2.07M 2.03M 87.38M 836K 936K 777K 707K 1.33M 88.69M 1.35M 9.33M 3.65M 46.27M 3.51M 3.44M 148M
Net income -4.26M -4.78M -3.96M -3.61M -6.78M -453M -6.91M -47.61M -18.63M -236M -17.93M -17.55M -756M -3.93M -4.41M -3.66M -3.33M -6.26M -417M -6.37M -43.93M -17.19M -218M -16.54M -16.19M -697M
Net Debt 3.54M 3.96M 3.29M 2.99M 5.63M 375M 5.73M 39.5M 15.46M 196M 14.88M 14.56M 627M 4.78M 5.35M 4.44M 4.04M 7.6M 507M 7.74M 53.34M 20.87M 265M 20.09M 19.66M 846M
Projected Income Statement - Annual - PREDILIFE
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
26-10-15 €0.8500 -5.56% 2
26-10-14 €0.9000 +1.12% 900
26-10-13 €0.8900 0.00% 0
26-10-12 €0.8900 0.00% 165
26-10-09 €0.8900 -2.20% 384

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - PREDILIFE
  1. Stock Market
  2. Stocks
  3. ALPRE Stock